Leela Morena

Leela Morena

Auto-generated profile, based on publicly available information

Leela Morena

Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
FHFrank Hullekes
Frank Hullekes
AUAudrey Uffing
Audrey Uffing
RVRucháma Verhoeff
Rucháma Verhoeff
HSHarald Seeger
Harald Seeger
SMSeraina von Moos
Seraina von Moos
LRLeonardo V. Riella
Leonardo V. Riella
Membranous nephropathy (MN) is a leading cause of kidney failure worldwide, and frequently recurs after transplant. Available data originated from small retrospective cohort studies or registry analyses. Therefore, uncertainties remain on risk factors for MN recurrence and response to therapy. Within the Post-Transplant Glomerular Disease (TANGO) Consortium, we conducted a retrospective multicenter cohort study examining the MN recurrence rate, risk factors, and response to treatment. This study screened 22,921 patients across three continents and included 194 patients who underwent a kidney transplant due to biopsy-proven MN. The cumulative incidence of MN recurrence was 31% at 10 years post-transplant. Patients with a faster progression towards end-stage kidney disease (ESKD) were at higher risk of developing recurrent MN (hazard ratio (HR) of 0.55 per decade (95%CI; 0.35-0.88). Moreover, elevated pre-transplant levels of anti-PLA2R antibodies were strongly associated with recurrence (HR 18.58; 95%CI; 5.37- 64.27). Patients receiving rituximab for MN recurrence had a higher likelihood of achieving remission than patients receiving RAAS inhibition alone. In sum, MN recurs in one-third of patients post-transplant and serum PLA2R antibodies shortly before transplant could aid in risk-stratifying patients for MN recurrence. Moreover, patients receiving rituximab had a higher rate of treatment response.

1 February 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
OGOrlando Vieira Gomes
Orlando Vieira Gomes
MGManoel Pereira Guimarães
Manoel Pereira Guimarães
JNJandir Mendonça Nicacio
Jandir Mendonça Nicacio
LMLeela Morena
Leela Morena
ASAntônio Marconi Leandro da Silva
Antônio Marconi Leandro da Silva
AAAnderson da Costa Armstrong
Anderson da Costa Armstrong
OBJECTIVE: The aim of this study was to investigate whether the degree of urbanization influences the prevalence of chronic kidney disease Brazilian indigenous people.METHODS: This is a cross-sectional study conducted between 2016 and 2017 in northeastern Brazil and includes individuals aged between 30 and 70 years from two specific indigenous groups who volunteered to participate in the study: the Fulni-o people (lowest degree of urbanization) and the Truka group (greater degree of urbanization). Cultural and geographical parameters were used to characterize and measure the magnitude urbanization. We excluded individuals with known cardiovascular disease or renal failure who required hemodialysis. Chronic kidney disease was defined as a single measurement of an estimated glomerular filtration rate <60 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration creatinine equation.RESULTS: A total of 184 indigenous people from the Fulni-o group and 96 from the Truka group with a median age of 46 years (interquartile range: 15.2) were included. We found a chronic kidney disease rate of 4.3% in the total indigenous population, generally affecting an older population: 41.7% over 60 years old (p<0.001). The Truka people had a chronic kidney disease prevalence of 6.2%, with no differences in kidney dysfunction across age groups. The Fulni-o participants had a chronic kidney disease prevalence of 3.3%, with a higher proportion of kidney dysfunction in older participants (of the six Fulni-o indigenous people with chronic kidney disease, five were older).CONCLUSION: Our results suggest that a higher degree of urbanization seems to negatively influence the prevalence of chronic kidney disease Brazilian indigenous people.

18 January 2026 in American Journal of Transplantation
Verified
Journal Article
Open access
DMDaniel M. Mendes
Daniel M. Mendes
JGJoão Ismael Budelon Gonçalves
João Ismael Budelon Gonçalves
KLKaifeng Liu
Kaifeng Liu
HCHeitor P.V. Da Costa
Heitor P.V. Da Costa
HCHugo Corrêa
Hugo Corrêa
LRLeonardo V. Riella
Leonardo V. Riella
Immunosuppressive drugs remain essential for preventing rejection but carry significant toxicities, underscoring the need for safer, physiology-based immunomodulators. Tributyrin, a prodrug of butyrate with improved systemic bioavailability, has emerged as a metabolically driven immune regulator. Here, we evaluated whether oral tributyrin promotes immune tolerance and improves graft outcomes in preclinical transplantation models. In minor-mismatch skin transplantation, tributyrin-treated recipients exhibited a significant, Treg-dependent prolongation of graft median survival time (33 [IQR 24.0-40.5] vs. 15.5 [IQR 12.0-18.0] days; p=0.0007). In a semi-allogeneic heart model, tributyrin similarly extended graft survival (52 [IQR 27.0-67.5] vs. 14.5 [IQR 12.25-22.0] days; p=0.0038). Oral tributyrin increased the frequency and activation of graft-infiltrating Tregs, marked by elevated IL-10, CTLA-4, LAG-3, and CD25, while reducing CD8+ T-cell infiltration and their IFN-γ and granzyme B production. Tributyrin treatment also modulated the intragraft innate compartment, reducing proinflammatory M1-macrophage signatures while promoting M2-macrophages with increased IL-10 expression. Systemically, splenocytes from treated recipients produced more IL-10 and displayed selective hyporesponsiveness to donor, but not to third-party antigens, consistent with antigen-specific regulation. Collectively, these findings demonstrate that oral tributyrin enhances regulatory pathways, suppresses alloreactive effector responses, and prolongs allograft survival, supporting its potential as a safe metabolic adjunct in transplantation.

30 December 2024 in JVS-Vascular Science
Verified
Journal Article
Open access
LMLeela Morena
Leela Morena
ICIsabella Ferlini Cieri
Isabella Ferlini Cieri
DMDaniel Marconi Mendes
Daniel Marconi Mendes
SFSasha P. Suarez Ferreira
Sasha P. Suarez Ferreira
SPShiv Patel
Shiv Patel
ADAnahita Dua
Anahita Dua
To investigate the mechanisms through which platelets and antiplatelet therapies modulate the immune response and propose directions for future research in this field, with a particular emphasis on their impact on treatment efficacy and surgical outcomes. A comprehensive review of recent studies investigating the role of platelets in immune modulation, specifically highlighting their involvement in pathogen recognition, leukocyte recruitment, and lymphocyte activation. Additionally, the review evaluates the impact of antiplatelet therapies, such as aspirin, P2Y12 inhibitors, and glycoprotein IIb/IIIa inhibitors, on immune responses. Recent studies have emphasized the critical role of platelets in immune-driven applications, namely, atherosclerosis, cancer, viral infections, and sepsis. These studies also suggest that antiplatelet therapies may alter immune responses. However, the precise mechanisms through which platelets and antiplatelet drugs influence immune responses, as well as their effects on post-treatment and surgical outcomes, are not yet fully elucidated. Recent studies highlight the important role of platelets in immune processes, such as in atherosclerosis, cancer, viral infections, and sepsis, and suggest that antiplatelet therapies can influence immune responses. However, the exact mechanisms by which platelets and antiplatelet drugs modulate these responses remain unclear. This area presents valuable opportunities for future research to uncover these mechanisms, which could lead to novel therapeutic strategies and better clinical outcomes for patients.